Poseida Therapeutics, Inc. Common Stock
PSTX
PSTX was delisted on the 7th of January, 2025.
56 hedge funds and large institutions have $288M invested in Poseida Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 22 increasing their positions, 11 reducing their positions, and 12 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 11
35% more capital invested
Capital invested by funds: $213M → $288M (+$75.1M)
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
8% more funds holding
Funds holding: 52 → 56 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
50% less call options, than puts
Call options by funds: $2K | Put options by funds: $4K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$10.6M |
| 2 |
BlackRock
New York
|
+$6.26M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.05M |
| 4 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$925K |
| 5 |
State Street
Boston,
Massachusetts
|
+$582K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$2.46M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$2.27M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$1.46M |
| 4 |
PVI
Pura Vida Investments
New York
|
-$1.32M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$820K |
PSTX Hedge Fund Activity: Q4 2020 in Review
56 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q4 2020, worth a combined $288M — up 35% from $213M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new PSTX positions and 12 closed out — a net gain of 4 holders — while 22 added to existing stakes and 11 trimmed.
The largest buyer was Millennium Management, adding an estimated $10.6M. The largest seller was UBS AM, exiting entirely with an estimated $2.46M sold.
- 56 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q4 2020, up from 52 in Q3 2020.
- Funds reported $288M of Poseida Therapeutics, Inc. Common Stock stock for Q4 2020, up 35% quarter-over-quarter.
- 16 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q4 2020 and 12 closed out, a net change of +4 holders.
- The largest Poseida Therapeutics, Inc. Common Stock buyer in Q4 2020 was Millennium Management, an estimated $10.6M added.
- The largest Poseida Therapeutics, Inc. Common Stock seller in Q4 2020 was UBS AM, an estimated $2.46M sold.
Based on aggregated 13F filings for Q4 2020.